Lymphoma clinical trials

Explore recruiting lymphoma clinical trials.

Recruiting lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1)

Germany, Greece, Austria

Therapeutic exploratory (Phase II) EU CTIS Study details

VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma

France, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Spain, France, Austria, Poland, Netherlands, Belgium +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase II trial investigating MOsunetuzumab and ZAnubrutinib (BGB-3111) in Relapsed/refracTory follicular lymphoma patients (MOZART)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

Finland, Spain, Denmark, Poland, Germany, France +3 more

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma

Czechia, Germany, Italy, Belgium, Spain, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Lymphoma trials by city

Lymphoma in Toronto Lymphoma in Vancouver Lymphoma in Montreal Lymphoma in Calgary Lymphoma in Edmonton Lymphoma in Ottawa Lymphoma in Winnipeg Lymphoma in Quebec City Lymphoma in Hamilton Lymphoma in Kitchener Lymphoma in London Lymphoma in Halifax Lymphoma in New York Lymphoma in Los Angeles Lymphoma in Chicago Lymphoma in Houston

Lymphoma clinical trials

Recruiting lymphoma studies right now

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India

A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

Also recruiting in Europe

Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1)

VALYM - A phase II open-label study evaluating valemetostat tosylate as a single agent in patients with relapse/refractory B-cell lymphoma

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

A phase II trial investigating MOsunetuzumab and ZAnubrutinib (BGB-3111) in Relapsed/refracTory follicular lymphoma patients (MOZART)

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma

Lymphoma trials by city

Other conditions